Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Research output: Contribution to journalJournal articleResearchpeer-review

Kamilla W Miskowiak, Maj Vinberg, Catherine J Harmer, Hannelore Ehrenreich, Lars V Kessing

Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.
Original languageEnglish
Issue number3
Pages (from-to)687-98
Number of pages12
Publication statusPublished - 2012

ID: 48496536